AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
AMN, AN, BAK, CBOE, and TPH have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2022.
Should Value Investors Pick AMN Healthcare Services (AMN)?
by Zacks Equity Research
Let's see if AMN Healthcare Services (AMN) stock is a good choice for value-oriented investors right now from multiple angles.
Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.
NextGen (NXGN)-Verato Tie Up to Improve Patient Insights
by Zacks Equity Research
NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q4 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.34% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.
AMN vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test
by Zacks Equity Research
Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.
AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe
by Zacks Equity Research
According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
by Zacks Equity Research
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
by Zacks Equity Research
LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
What's in Store for West Pharmaceutical's (WST) Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.
Baxter (BAX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.
Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore
by Zacks Equity Research
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.
Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass
by Zacks Equity Research
Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.